scholarly journals Maternal Experience of Domestic Violence, Associations with Children’s Lipid Biomarkers at 10 Years: Findings from MINIMat Study in Rural Bangladesh

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 910
Author(s):  
Shirin Ziaei ◽  
Ruchira Tabassum Naved ◽  
Anisur Rahman ◽  
Rubhana Raqib ◽  
Eva-Charlotte Ekström
Keyword(s):  
Domestic Violence ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Biomarkers ◽  
Maternal Experience ◽  
Before And After ◽  
Controlling Behavior ◽  
Controlling Behaviors

The consequences of maternal experience of Domestic Violence (DV) on their children’s cardio-metabolic risk factors are unclear. We aimed to assess if maternal exposure to any or a specific form of DV (i.e., physical, sexual, emotional and controlling behaviors) before and after childbirth was associated with their children’s lipid biomarkers at the age of 10 years. A current observational sub-study of a larger MINIMat trial included a cohort of 1167 mothers and their children. The conflict tactic scale was used to record women’s experience of lifetime DV before and after childbirth at week 30 of pregnancy and at a 10-year follow up, respectively. Five ml of fasting blood sample was collected from the children to evaluate their lipid profile. Children of women who experienced any DV before childbirth had lower Apo A (βadj −0.04; 95% CI: −0.08, −0.01). Women who experienced physical DV both before and after childbirth had children with higher triglycerides (βadj 0.07; 95% CI: 0.01, 0.14). Children whose mother experienced sexual DV before birth had lower Apo A (βadj −0.05; 95% CI: −0.08, −0.01) and High Density Lipoprotein (HDL) (βadj −0.05; 95% CI: −0.10, −0.01) as well as higher Low Density Lipoprotein (LDL) (βadj 0.17; 95% CI: 0.05, 0.29) and LDL/HDL (β 0.24; 95% CI: 0.11, 0.38). However, levels of LDL (βadj −0.17; 95% CI: −0.28, −0.06), LDL/HDL (βadj −0.12; 95% CI: −0.25, −0.00) and cholesterol (βadj −0.13; 95% CI: −0.25, −0.02) were lower among the children of mothers who experienced controlling behavior after childbirth. Results from the current study suggest that maternal experience of physical or sexual DV might negatively affect their children’s lipid profile at the age of 10 years.

Melatonin Improves Lipid Profile and Ameliorates Lipid Peroxidation in Patients with Chronic Kidney Disease.

2018 ◽  
pp. 38-45
Keyword(s):  
Lipid Peroxidation ◽  
Placebo Group ◽  
Lipid Profile ◽  
Kidney Diseases ◽  
Oxidized Ldl ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Before And After ◽  
Inhibit Lipid Peroxidation ◽  
Controlled Clinical Study

Dyslipidemia and oxidative modifications of lipid are frequently associated in patients with chronic kidney diseases (CKD) and considered the most important risk factors for cardiovascular events. Melatonin is a well-known potent antioxidant and has beneficial effect on lipid metabolism. the study was designed to evaluate if Melatonin could improve lipid profile and ameliorates lipid peroxidation. This single blind placebo controlled clinical study carried out on 41 patients with CKD who were randomized into two groups, control groups (n=20) those who received placebo cap and melatonin group those who received 5mg melatonin (n=21). Lipid profile [total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C)] and parameters of lipid peroxidation [oxidized LDL (oxLDL) and malondialdehyde (MDA) were measured before and after 12 weeks of the treatment. After 12 weeks of treatment, melatonin significantly increased HDL-C and decreased LDL-C compared to the initial value. The elevation in HDL-C and reduction in LDL-C were significantly different from that in placebo group. Also, both oxLDL and MDA levels significantly lowered by melatonin compared to the baseline and to the placebo group. Collectively, the results of our study showed that melatonin has advantageous effect on lipid profile and inhibit lipid peroxidation in patients with CKD.

Impact of One-Rod Levonorgestrel Implant on Blood Chemistry Profile

2021 ◽  
Author(s):  
Eka R. Gunardi ◽  
Raymond Surya ◽  
Inayah Syafitri ◽  
Yogi Pasidri
Keyword(s):  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Chemistry ◽  
Rank Test ◽  
Bivariate Analysis ◽  
Signed Rank ◽  
Before And After ◽  
Signed Rank Test ◽  
Aspartate Transferase

Abstract Objective: The aim of this study is to investigate the effect of one-rod levonorgestrel implant on the blood chemistry profile which include random blood glucose (RBG), hemoglobin (Hb), alanine transferase (ALT), aspartate transferase (AST), and lipid profile such as total cholesterol, High-density lipoprotein (HDL), Low-density lipoprotein (LDL), and triglycerideMethods: This prospective cohort study was conducted at Raden Saleh Clinic, Jakarta from 2010 to 2012. The implants were inserted subdermally in 30 patients. The subjects were evaluated for 6 months and the blood chemistry profile was followed up to 2 years. Bivariate analysis using t-test or Wilcoxon signed rank test was performed for all variables. The p <0.05 was considered as a significant value. Results: The level of Hb, RBG, AST, and lipid profile was different significantly before and after 6-months one-rod implant insertion (p<0.05). However, in 24 months, all of parameters were still on normal limit and not different clinically. Conclusion: One-rod levonorgestrel implant insertion shows minimal effect to all blood chemistry profiles.

scholarly journals Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial

2018 ◽  
Vol 6 (4) ◽  
pp. 165-171
Author(s):  
Hamid Noshad ◽  
Davoud Mohammadi Nejhad ◽  
Parastou Hoseini ◽  
Majid Montazer ◽  
Behnaz Ghamari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Randomised Clinical Trial ◽  
Hemodialysis Patients ◽  
The Other ◽  
Medical Sciences ◽  
Before And After

Introduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carnitine combination versus atorvastatin alone on the lipid profile of hemodialyzed patients. Methods: In this clinical trial, 50 hemodialysis patients referred to the educational centres of Tabriz University of Medical Sciences, Tabriz, Iran, for haemodialysis were enrolled. Patients were randomly assigned into two groups. In the first group, patients were treated with carnitine (1000 mg three times daily) and atorvastatin (10-80 mg/day based on the baseline lipid profile of the patients) and in the second group, the patients were treated with atorvastatin alone for six months. The levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin before and after intervention were compared. The side effects of carnitine administration were also evaluated. Results: Results showed that TG, cholesterol, and LDL levels were significantly lower in the carnitine group compared to those in the other group at the end of study (P < 0.050). In addition, HDL and haemoglobin levels were significantly higher in the carnitine group in comparison to the other group (P < 0.050). No major side effects of carnitine were observed among the patients. Conclusion: The use of carnitine plus atorvastatin combination is an effective and safe method in the treatment of dyslipidemia in patients undergoing hemodialysis without imposing significant side effects.

Identification of Undiagnosed Hyperlipidemia: Do Work Site Screening Programs Work?

2016 ◽  
Vol 32 (4) ◽  
pp. 971-978 ◽  
Author(s):  
Alain K. Koyama ◽  
Vishal Bali ◽  
Irina Yermilov ◽  
Antonio P. Legorreta
Keyword(s):  
Lipid Profile ◽  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
The United States ◽  
Workplace Health ◽  
Subsequent Increase ◽  
Physician Visits ◽  
Screening Programs

Purpose: We evaluated the rate of hyperlipidemia identified during workplace screening in previously undiagnosed individuals, the association between workplace hyperlipidemia screening and use of medical care during follow-up, and changes in lipid profile among individuals with hyperlipidemia at screening. Design: Nonexperimental longitudinal study. Setting: Employees who participated in a workplace health screening. Participants: A total of 18 993 individuals from 39 self-insured employers in the United States. Measures: Total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides were measured during screening. A claims-based algorithm was used to identify hyperlipidemia cases. Analysis: Discrete-time survival analysis was used to estimate monthly rates of new hyperlipidemia diagnoses or prescriptions. Paired t tests were used to evaluate 1-year changes in lipid profile. Results: A total of 1872 (9.9%) individuals had hyperlipidemia at screening. Among all individuals, a significantly greater rate of new hyperlipidemia diagnoses was observed during the first month after screening, compared to the 3 months before screening (odds ratio [95% CI]: 2.99 [2.66-3.36]). Among the 987 individuals who were followed up 1 year later, significant improvements were observed in total cholesterol (−8.5% ± 13.6%) and LDL levels (−10.2% ± 19.3%). Conclusion: Workplace health screenings in an insured population were associated with a subsequent increase in physician visits and prescriptions for hyperlipidemia. After 1 year, significant improvements in total cholesterol and LDL levels were observed among individuals who screened positive for hyperlipidemia.

scholarly journals ALTERATION IN SERUM LIPID PROFILE LEVELS IN IRAQI WOMEN WITH BREAST CANCER BEFORE AND AFTER CHEMOTHERAPY

2018 ◽  
Vol 11 (5) ◽  
pp. 230
Author(s):  
Rana Hazim Hamoode ◽  
Mohammed Qais Al-ani ◽  
Fareed Arrak Turkey
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Control Group ◽  
Before And After ◽  
Medical City ◽  
Progression Of Disease ◽  
Iraqi Women

Objective: Investigating the role of alterations in lipid profile in Iraqi women with breast cancer before and after chemotherapy.Methods: A total number of 100 patients aged 25–47 years were enrolled in this study, including 35 breast cancer treatment patients, 30 treatment patients, and 10 and 25 healthy women benefactor. All samples were collected from August 2016 to February 2017 from Oncology Hospital/Medical city in Baghdad; however, control group samples were collected from outside the hospital. Serum total cholesterol, serum triglyceride, and serum high-density lipoprotein cholesterol (HDL-C) were measured by spectrophotometer using a kit provided by Linear Chemicals.Results: The results show a highly significant increment (p˂0.01) in lipid profile in breast cancer, especially in diagnosis group as compared with other groups.Conclusion: The alteration in cholesterol, triglyceride, HDL-C, and very low-density lipoprotein is highly connected with breast cancer in Iraqi women, progression of disease and treatment effect.

AB0440 LDL-CHOLESTEROL AS A RISK FACTOR OF PROGRESSION TO ESRD IN PATIENTS WITH LUPUS NEPHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1519.1-1519
Author(s):  
D. J. Park ◽  
S. E. Choi ◽  
H. Xu ◽  
J. H. Kang ◽  
S. S. Lee
Keyword(s):  
Regression Analysis ◽  
Risk Factor ◽  
Lupus Nephritis ◽  
Lipid Profile ◽  
Kidney Biopsy ◽  
Clinical Laboratory ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Immunosuppressive Drugs

Background:Objectives:There are few data on the effect of dyslipidemia in patients with lupus nephritis (LN). Thus, we investigated the effect of low-density lipoprotein-cholesterol (LDL-C) on the progression to end-stage renal disease (ESRD) in patients with biopsy-proven LN.Methods:We followed 121 LN patients who underwent kidney biopsy and were subsequently treated with immunosuppressive drugs. Sociodemographic, clinical, laboratory (including lipid profile), and treatment-related data at the time of kidney biopsy and during follow-up were obtained by a review of patients’ charts. Patients were divided into two groups related to the mean LDL-C level: <100 mg/dL and ≥100 mg/dL. Cox’s proportional regression analysis was performed to identify the independent predictors of progression to ESRD in LN patients.Results:Seventy-one of 121 biopsy-proven LN patients (58.7%) showed more than 100 mg/dL of LDL-C at the time of LN diagnosis. The higher LDL-C group excreted more 24-hour urine protein (p=0.003), and showed a higher proportion of proliferative LN (p=0.013) and an activity score >12 (p=0.023). During a mean follow-up of 83.0 (range, 12–171) months, ESRD was more frequent in the higher LDL-C group than in the lower group (15.5% vs. 2.0%; p=0.012). In the multivariate Cox’s proportional regression analysis, LDL-C ≥100 mg/dL (hazard ratio [HR], 171.340; p=0.012), estimated glomerular filtration rate during the renal biopsy (HR, 0.977; p=0.005), statin exposure during follow-up (HR, 0.163; p=0.031), relapse (HR, 9.752; p=0.036), and complete remission at 1-year of treatment (HR, 0.034; p=0.003) were significant predictors of progression to ESRD in LN patients.Conclusion:Our findings suggest that dyslipidemia at the onset of LN is an independent risk factor for predicting the development of ESRD in LN patients. Therefore, lipid profile should be monitored carefully and managed aggressively to avoid the deterioration of kidney function in patients with LN.Disclosure of Interests:None declared

scholarly journals SIMVASTATIN GENERIK

2018 ◽  
Vol 20 (2) ◽  
pp. 107
Author(s):  
DAP. Rasmika Dewi ◽  
DG. Diah Dharma Santhi ◽  
DM Sukrama ◽  
AA. Raka Karsana
Keyword(s):  
Statistical Analysis ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
P Value ◽  
Low Density ◽  
Serum Samples ◽  
Significant Difference ◽  
Before And After

This study aims to know and determine the lipid profile in patients with hyperlipidemia who consumed Generic Simvastatin comparedwith its patent product contained in the Formularium at Sanglah Hospital. The observations made, were the measurement of the totalcholesterol and low-density lipoprotein (LDL) before and after the drug administration. A total of 30 subjects who met the inclusioncriteria, were divided into two (2) groups, each group consist of 15 persons, the first group was given 20 mg generic Simvastatin(1 tablet daily) for 15 days and Group II given 20 mg patent Simvastatin (1 tablet daily) for 15 day. After 15 days, their blood sampleswere taken and examined for total cholesterol and LDL. Once the data were collected, statistical analysis was done by using the normalitytest, homogeneity and t. Statistical analysis using p-value less than or equal to 0.05 was the limit of significance. The statistical analysisshowed that the data was normally distributed and homogeneous (p≥0.05). The T-test showed that there were significant differencesin the levels of total cholesterol and LDL serum samples before and after the administration of generic simvastatin and patents the(sig.=0.000). However, there was no significant difference in decreased levels of totall cholesterol samples between the generic Simvastatinand patent (sig=0.365 with α=0.05 level). Besides this, there was also no significant difference in the decreased levels of LDL betweengeneric Simvastatin and the patent one (sig=0.372 with α=0.05 level).

scholarly journals Lipid Status During Combined Treatment in Prostate Cancer Patients

2019 ◽  
Vol 13 (5) ◽  
pp. 155798831987648
Author(s):  
Edyta Wolny-Rokicka ◽  
Andrzej Tukiendorf ◽  
Jerzy Wydmański ◽  
Małgorzata Ostrowska ◽  
Agnieszka Zembroń-Łacny
Keyword(s):  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Combined Treatment ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Lipid Status ◽  
Before And After ◽  
The Mean ◽  
Lipid Parameters

The aim of this study was to provide a specific review of current medical literature regarding the lipid profile during prostate carcinoma (PCa) treatment. The main aim was to analyze the results presented by different authors and to find a commonality in the changes occurring during the treatment—hormonotherapy. The levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured before and after the follow-up treatment. The manuscripts reviewed came from the period between 2008 and 2016. The size of the studies ranged from 16 participants to 310. The mean age was from 65 to 74 years in all studies. The Q test was used to attain all lipid parameters and to specify heterogeneity ( p < .0001). After 12 months of androgen deprivation therapy (ADT), the patients had a significantly higher level serum TC and TG.

scholarly journals One month Ramadan Fast Improves Lipid Profile Status of Bangladeshi Male Volunteers

2013 ◽  
Vol 18 (2) ◽  
pp. 37-42
Author(s):  
Md Bazlul Karim Choudhury ◽  
Taufiqur Rahman ◽  
Mst Masuda Begum ◽  
Afsana Ahmed ◽  
Md Shahdat Hossain ◽  
...  
Keyword(s):  
Heart Disease ◽  
Molecular Biology ◽  
Ischemic Heart Disease ◽  
High Density Lipoprotein ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Before And After

To evaluate the effect of Ramadan fast on serum lipid profile status of men, the study was carried out in the National Mushroom Development and Extension Centre, Sobhanbag, Savar Dhaka in association with the Department of Pharmacy and Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka. The experiment was conducted before and after the Arabic month, Ramadan, when there occurs a change both in the pattern and timing of dietary intake. Findings of the study shows Ramadan fast significantly reduced serum Low Density Lipoprotein (LDL-C) (p = 0.011). A statistically non significant reduction of total Cholesterol (TC) (p = 0.340), small elevation of High Density Lipoprotein (HDL-C) (p = 0.252) and Triglyceride (TG) (p = 0.502) were also observed. Considering the findings of the study it was noticeable that one month Ramadan fast can improve lipid profile status of blood and hence able to improve atherosclerotic diseases which includes hypertension, ischemic heart disease and stroke. DOI: http://dx.doi.org/10.3329/jdnmch.v18i2.16021 J. Dhaka National Med. Coll. Hos. 2012; 18 (02): 37-42

scholarly journals The Correlation of Use of Depo Medroxy Progesterone Acetate (DMPA) In-jections with Lipid Profile Levels in Rats

2021 ◽  
Vol 4 (1) ◽  
pp. 27-31
Author(s):  
Suratiah Suratiah ◽  
Dewa Ayu Surinati ◽  
I Dewa Gede Putu Putra Yasa
Keyword(s):  
Lipid Profile ◽  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Control Group ◽  
Control Group Design ◽  
Cholesterol Levels ◽  
Significant Difference ◽  
Before And After ◽  
Long Time

Introduction: Family Planning is a national strategy of Indonesia government to manage the population growth. Depo Medroxyprogesterone Acetate (DMPA) is one of injectable contraceptives most widely used because it is simple and easy to obtain. However, it has various side effects causing imbalance of hormone estrogen, in turns to result in a decrease in HDL (High Density Lipoprotein) and an increase in LDL (Low Density Lipoprotein) which will result in an increase in total cholesterol. It will also affect changes in fat metabolism in human body due to hormonal influences. This results in dyslipidemia and atherosclerosis. Method: The method in this study is an experimental study with a pretest-posttest control group design. Results: The purpose of this study was to determine the relationship between duration of use of DMPA injections with lipid profile levels in mice. The data were analyzed by using the Paired t-test parametric test to compare between treatment groups. This study found that there were significant differences in HDL levels and total cholesterol levels between before and after administration of DMPA injections on the 14th and 35th days. There is a significant relationship between the duration of administration of DMPA injections with HDL levels and total cholesterol levels in mice. However, there was no difference in LDL levels and triglyceride levels between before and after administration of DMPA injection on day of 14 and day of 35, while, there was a significant difference between before and after the 35th day. There is no relationship between duration of administration of DMPA injections with LDL levels, while there is a relationship among mice triglycerides. Conclusions: Administration of DMPA injections for a long time lowers HDL.

Sign in / Sign up

Export Citation Format

Share Document